Immunoglobulin Light-chain Amyloidosis: all 174 studies
Page 1 of 2. Open to participants first (58), then studies with results posted, then the rest; newest registration first within each.
- Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain AmyloidosisNot yet recruitingNCT07874334Phase 1
- SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell DisordersRecruitingNCT07850284
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisNot yet recruitingNCT07793422Phase 3
- PET Imaging With [18F]Fluselenamyl in People With Cardiac AmyloidosisEnrolling by invitationNCT07771621Phase 1
- A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL AmyloidosisNot yet recruitingNCT07765524Phase 1/2
- BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)Not yet recruitingNCT07751471Phase 2
- Hungarian National Systemic Amyloidosis RegistryRecruitingNCT07689331
- A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).RecruitingNCT07638683Phase 2
- Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine ImagingNot yet recruitingNCT07624760Not applicable
- A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue InvolvementNot yet recruitingNCT07615270Early Phase 1
- Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) AmyloidosisNot yet recruitingNCT07524634Phase 2
- One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSRecruitingNCT07448935
- Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentRecruitingNCT07448779
- Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL AmyloidosisRecruitingNCT07335887Phase 2
- Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisRecruitingNCT07250269Phase 1
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingNCT07224672Phase 2
- A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain AmyloidosisRecruitingNCT07215494Not applicable
- BE.Amycon Biobank & Data Registry UZ LeuvenRecruitingNCT07172243
- Teclistamab-Daratumumab in AL AmyloidosisRecruitingNCT07110844Phase 2
- Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis PrognosisEnrolling by invitationNCT07103863
- Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical ResearchRecruitingNCT07085559Early Phase 1
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.RecruitingNCT07081646Phase 1/2
- Teclistamab in Newly Diagnosed Mayo Stage IIIB AL AmyloidosisRecruitingNCT07079423Phase 2
- Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL AmyloidosisNot yet recruitingNCT07055724Phase 2
- Evaluation of Skin Tests in Biotherapy AllergiesRecruitingNCT06971848Not applicable
- Teclistamab in Previously Treated AL AmyloidosisRecruitingNCT06935162Phase 2
- Essen Amyloidosis RegistryRecruitingNCT06887283
- The Norwegian Immunotherapy in Multiple Myeloma StudyRecruitingNCT06855121
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
- Prospective Study of Teclistamab in the Treatment of Systemic AL AmyloidosisRecruitingNCT06699394Not applicable
- Rapid dFLC Response Predict CHR in AL AmyloidosisRecruitingNCT06627309
- Elranatamab in Patients With Relapsed or Refractory AL AmyloidosisRecruitingNCT06569147Phase 1/2
- Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyRecruitingNCT06455748Not applicable
- Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDDRecruitingNCT06418477Phase 2
- Promoting Diagnosis and Management of AL in Italy (ProDigALIty)RecruitingNCT06383143
- Screening for AL Amyloidosis in Smoldering Multiple MyelomaRecruitingNCT06365060
- Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisRecruitingNCT06342466Phase 2
- A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)RecruitingNCT06205953
- Optimize First-line Treatment for AL Amyloidosis With t (11; 14)RecruitingNCT06192979Not applicable
- Amyloidosis Incidence in High-Risk Cardiac Device PatientsRecruitingNCT06186167
- National Registry of Rare Kidney DiseasesRecruitingNCT06065852
- 18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL AmyloidosisRecruitingNCT06048601Not applicable
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingNCT06022939Phase 3
- A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic AmyloidosisRecruitingNCT05951816Phase 1
- Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA TrialRecruitingNCT05898646Phase 2
- Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL AmyloidosisNot yet recruitingNCT05776940Phase 3
- The Italian Transthyretin Amyloidosis Web-NetworkRecruitingNCT05444920
- A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous DaratumumabRecruitingNCT05277493
- Cardiac Amyloidosis Registry StudyEnrolling by invitationNCT05174338
- Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisRecruitingNCT05145816Phase 1/2
- Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous TherapyRecruitingNCT05066607Phase 2
- A Registry of AL Amyloidosis (ReAL)RecruitingNCT04839003
- Autologous Stem Cell Transplantation for Patients With AL AmyloidosisEnrolling by invitationNCT04210791
- Molecular Imaging of Primary Amyloid CardiomyopathyRecruitingNCT02641145Not applicable
- Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample ResourceRecruitingNCT01408225
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Collection of Samples and Clinical Data From Patients With Amyloid DiseasesRecruitingNCT00898235
- Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid LoadCompletedNCT05968846Phase 2Results posted
- COVID-19 VAX Booster Dosing in Patients With Hematologic MalignanciesCompletedNCT05028374Phase 2Results posted
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)Active, not recruitingNCT04512235Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)Active, not recruitingNCT04504825Phase 3Results posted
- A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL AmyloidosisCompletedNCT04304144Phase 2Results posted
- S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary AmyloidosisCompletedNCT03499808Phase 2Results posted
- Study in Subjects With Light Chain (AL) AmyloidosisTerminatedNCT03154047Phase 2Results posted
- Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis PatientsTerminatedNCT02994784Phase 2Results posted
- Daratumumab for the Treatment of Patients With AL AmyloidosisCompletedNCT02841033Phase 1/2Results posted
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) AmyloidosisCompletedNCT02632786Phase 2Results posted
- Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) AmyloidosisTerminatedNCT02613182Phase 2Results posted
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL AmyloidosisCompletedNCT02545907Phase 1/2Results posted
- Trial of High Dose Melphalan/Stem Cell Transplant With or Without BortezomibTerminatedNCT02489500Phase 3Results posted
- Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis TrialCompletedNCT02207556Phase 2Results posted
- Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaCompletedNCT01849783Phase 2Results posted
- A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL AmyloidosisCompletedNCT01570387Phase 1/2Results posted
- Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL AmyloidosisCompletedNCT01383759Not applicableResults posted
- Bendamustine and Dexamethasone in Patients With Relapsed AL AmyloidosisCompletedNCT01222260Phase 2Results posted
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain AmyloidosisCompletedNCT01078454Phase 3Results posted
- Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain AmyloidosisCompletedNCT01072773Phase 2Results posted
- A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL AmyloidosisCompletedNCT00890552Not applicableResults posted
- Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00790647Phase 2Results posted
- Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00679367Phase 2Results posted
- Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom BurdenCompletedNCT00651937Phase 2Results posted
- Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00564889Phase 2Results posted
- High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
- Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition DiseaseCompletedNCT00520767Phase 2Results posted
- Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00477971Phase 3Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00091260Phase 2Results posted
- S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic AmyloidosisCompletedNCT00064337Phase 2Results posted
- Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain AmyloidosisWithdrawnNCT07626476Early Phase 1
- Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug ResistanceCompletedNCT07585331
- Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain AmyloidosisWithdrawnNCT06983951Not applicable
- A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisWithdrawnNCT06963216Phase 3
- BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction TherapyWithdrawnNCT06769555Not applicable
- A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) AmyloidosisActive, not recruitingNCT06649695Phase 2
- AL Amyloidosis and Anti-CD38-DaratunumabCompletedNCT06571864Not applicable
- Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisActive, not recruitingNCT06097832Phase 1/2
- FKC288 for Relapsed or Refractory Systemic Light Chain (AL) AmyloidosisStatus unknownNCT05978661Phase 1
- A Study of AT-02 in Subjects With Systemic Amyloidosis.Active, not recruitingNCT05951049Phase 2
- A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)TerminatedNCT05839626Phase 1